Harnessing the CD1 restricted T cell response for leukemia adoptive immunotherapy

M Consonni, C de Lalla, A Bigi, P Dellabona, G Casorati

Research output: Contribution to journalArticlepeer-review


Disease recurrence following chemotherapy and allogeneic hematopoietic cell transplantation is the major unmet clinical need of acute leukemia. Adoptive cell therapy (ACT) with allogeneic T lymphocytes can control recurrences at the cost of inducing detrimental GVHD. Targeting T cell recognition on leukemia cells is therefore needed to overcome the problem and ensure safe and durable disease remission. In this review, we discuss adoptive cells therapy based on CD1-restricted T cells specific for tumor associated self-lipid antigens. CD1 molecules are identical in every individual and expressed essentially on mature hematopoietic cells and leukemia blasts, but not by parenchymatous cells, while lipid antigens are enriched in malignant cells and unlike to mutate upon immune-mediated selective pressure. Redirecting T cells against self-lipids presented by CD1 molecules can thus provide an appealing cell therapy strategy for acute leukemia that is patient-unrestricted and can minimize risks for GVHD, implying potential prognostic improvement for this cancer. © 2017 Elsevier Ltd
Original languageEnglish
Pages (from-to)117-123
Number of pages7
JournalCytokine and Growth Factor Reviews
Issue number7
Publication statusPublished - 2017

Fingerprint Dive into the research topics of 'Harnessing the CD1 restricted T cell response for leukemia adoptive immunotherapy'. Together they form a unique fingerprint.

Cite this